The Prostate Cancer Program (05) has 3 central themes: 1) mechanisms of castration resistance;2) molecular targeting;and 3) translational studies, both clinical and preclinical. The major program emphasis is on the study of the mechanisms of aberrant androgen receptor (AR) activation in the development of castration resistant prostate cancer (CRPC). Studies to understand the function and regulation of AR divide into 3 areas: a) regulation of intracrine androgens, b) aberrant AR activation, and c) the role of co-regulators. Molecular targeting of CRPC focuses on the role of neuropeptides, kinase inhibitors, and the role of autophagy. In translational studies, eight different targets are under investigation, four of which have progressed to investigator-initiated clinical trials. Our long-term goal is to develop mechanism-based treatments for CRPC and castration-adjunctive therapy that may lead to a more effective intervention than castration alone. The program has 17 members from 8 different departments and divisions. It has 8 NCl-funded projects for $1.1 million ADC (total peer-reviewed funding, $3.1 million ADC). The group has 320 publications;54% are inter-programmatic and 26% are intra-programmatic

Public Health Relevance

Patients die of prostate cancer because the tumors learn to bypass the effects of therapeutic strategies aimed at reducing the supply of androgens to the cancer. This is called castration resistant prostate cancer. The program is aimed at understanding why this occurs, attempting to prevent its occurrence, and developing therapies to treat it once it has occurred.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA093373-12
Application #
8743643
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
12
Fiscal Year
2014
Total Cost
$22,223
Indirect Cost
$7,745
Name
University of California Davis
Department
Type
DUNS #
047120084
City
Davis
State
CA
Country
United States
Zip Code
95618
Zeng, Shu-Xiong; Zhu, Yanjun; Ma, Ai-Hong et al. (2017) The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clin Cancer Res 23:6580-6591
Zhong, Cheng; Han, Ju; Borowsky, Alexander et al. (2017) When machine vision meets histology: A comparative evaluation of model architecture for classification of histology sections. Med Image Anal 35:530-543
Gingrich, Alicia A; Elias, Alexandra; Michael Lee, Chia-Yuan et al. (2017) Predictors of residual disease after unplanned excision of soft tissue sarcomas. J Surg Res 208:26-32
Li, Tianhong; Piperdi, Bilal; Walsh, William V et al. (2017) Randomized Phase 2 Trial of Pharmacodynamic Separation of Pemetrexed and Intercalated Erlotinib Versus Pemetrexed Alone for Advanced Nonsquamous, Non-small-cell Lung Cancer. Clin Lung Cancer 18:60-67
York, D; Sproul, C D; Chikere, N et al. (2017) Expression and targeting of transcription factor ATF5 in dog gliomas. Vet Comp Oncol :
Yap, Stanley A; Yuh, Lindsay M; Evans, Christopher P et al. (2017) Evolving patterns of care in the management of stage I non-seminomatous germ cell tumors: data from the California Cancer Registry. World J Urol 35:277-283
(2017) New and emerging developments in extensive-stage small cell lung cancer therapeutics: Erratum. Curr Opin Oncol 29:88
Johnson, Lianna M; Du, Jiamu; Hale, Christopher J et al. (2017) Corrigendum: SRA- and SET-domain-containing proteins link RNA polymerase V occupancy to DNA methylation. Nature 543:136
Jian, Chao; Tu, Mei-Juan; Ho, Pui Yan et al. (2017) Co-targeting of DNA, RNA, and protein molecules provides optimal outcomes for treating osteosarcoma and pulmonary metastasis in spontaneous and experimental metastasis mouse models. Oncotarget 8:30742-30755
Wan, Debin; Yang, Jun; Barnych, Bogdan et al. (2017) A new sensitive LC/MS/MS analysis of vitamin D metabolites using a click derivatization reagent, 2-nitrosopyridine. J Lipid Res 58:798-808

Showing the most recent 10 out of 733 publications